CareDx, Inc. 8-K

What Happened

• On February 24, 2026, CareDx, Inc. announced its financial results for the quarter ended December 31, 2025 via a press release attached to the 8-K as Exhibit 99.1.
• The company also disclosed that Nathan Smith resigned as Chief Financial Officer effective at the close of business on February 25, 2026, and that the Board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer effective February 26, 2026. Mr. Kennedy has been designated CareDx’s principal financial officer and principal accounting officer. The company stated Mr. Smith’s departure was for personal reasons and not due to any disagreement about financial statements or disclosures.

Key Details

• Press release announcing quarterly results filed as Exhibit 99.1 (quarter ended Dec. 31, 2025).
• Keith Kennedy (age 56) served as CareDx Chief Operating Officer since Sept. 2024; previously CFO roles at PharmaLogic Holdings and Veracyte; holds a B.S. in Accounting (Indiana University), an MBA (William & Mary), and is a CFA and CPA.
• Separation package for Nathan Smith (to be set forth in a Release Agreement to be filed in the next 10-Q) includes: a lump‑sum cash payment equal to nine months of his base salary; 2025 bonus of $91,643; reimbursement of COBRA premiums for nine months (subject to election); and vesting of 5,840 restricted stock units (pro rata vesting through separation date).
• The company posted an updated corporate presentation on its website current as of February 24, 2026 and included the customary forward‑looking statements caution.

Why It Matters

• For investors, the filing combines two material items: the company’s quarterly earnings release (earnings/quarterly results) and a near‑term change in the finance leadership team. Appointing an experienced finance executive (Keith Kennedy) and designating him as principal financial and accounting officer aims to maintain continuity in financial reporting and operations.
• The financial impact of the CFO separation will include the specified cash and equity vesting items (noted above) and will be detailed further in upcoming filings (the Release Agreement will be filed with the March 31, 2026 10-Q). Investors should review the attached press release and updated corporate presentation for the company’s reported results and any commentary management provides.